ADA Forsyth ranks number 1 on the East Coast in oral health research
The oral health research institute also placed 4th nationally in total NIDCR funding awarded to dental institutions
2024-05-03
(Press-News.org) Cambridge, Mass., – ADA Forsyth Institute (AFI) researchers received just under $10 million funding from the National Institute of Dental and Craniofacial Research (NIDCR) during the federal fiscal year 2023, placing 4th nationally on NIDCR’s ranking list.
“We have ranked in the top 5 dental institutions in 9 out of the past 10 years,” said Wenyuan Shi, PhD, Chief Executive Officer of AFI. “We have placed in the top 10 nationally every year since the ranking system began in 2002, despite having one of the smallest faculty sizes among all ranked programs.” The institute has also ranked number 1 in Boston every year since 2009. It should be noted that the NIDCR funding rank list only includes prime awards, not subawards.
Located in Cambridge, Massachusetts, ADA Forsyth is a non-profit research institution with a rich legacy of groundbreaking scientific breakthroughs spanning microbiology, immunology, and mineralized tissue biology.
“Congratulations to all the researchers at AFI and our amazing collaborators around the world,” said Ben Wu, PhD, DDS, Chief Operating Officer and Chief Scientific Officer at AFI. “The sustained excellence and double-digit growth (17.4%) in FY2023 are truly impressive. Our relocation to a state-of-the-art research facility in 2025 will substantially enhance our research infrastructure and scientific instrumentation, ensuring the expansion of our innovative team and perpetuation of excellence.”
###
About the ADA Forsyth Institute
The ADA Forsyth Institute was founded in 1910 as the Forsyth Dental Infirmary for Children (later, the Forsyth Institute), to provide dental care to the disadvantaged children of Boston. While continuing to serve children in need, yet recognizing the ultimate goal is to prevent dental disease, the Institute in 1915 began to focus on scientific research and is today the world’s leader in oral health research. In October of 2023, the Institute joined with the American Dental Association to form the ADA Forsyth Institute, a 501(c)(3) entity dedicated to improving people’s oral and overall health and powering the profession of dentistry through cutting-edge basic research, creative translational science, innovative clinical technologies, and global public health outreach. Consistent with the Institute’s founding mission, the ADA ForsythKids mobile dental program continues to serve children in need.
Media Contacts:
ADA Forsyth, Jill Sirko, jsirko@forsyth.org
ADA Media Relations, mediarelations@ada.org
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2024-05-03
May 3, 2024—CHICAGO—The American Ornithological Society (AOS) is pleased to announce Judit K. Szabo, Ph.D., as the incoming editor-in-chief for its top-ranked journal, Ornithological Applications. Beginning on May 1, 2024, Szabo will work in partnership with the journal’s current editor-in-chief, Catherine Lindell, Ph.D., until June 30, 2024, and will take on full responsibility as editor-in-chief beginning on July 1, 2024. “With her international interest and network, conservation experience, and thoughtful approach ...
2024-05-03
Long Beach, Calif. – May 3, 2024 – New data from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AX) demonstrated that catheter-directed mechanical thrombectomy is safe and effective in patients with acute intermediate-risk pulmonary embolism (PE) with significant improvement in the right ventricle (RV) function and minimal major adverse events. The safety and efficacy results from the prospective trial were presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
Pulmonary embolism (PE), a blood clot that blocks and stops ...
2024-05-03
Long Beach, Calif. – May 3, 2024 – Late-breaking data from the ENGULF trial showed that a novel dual-action thrombectomy device was effective and safe in treating acute pulmonary embolism (PE). The safety and effectiveness results were presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and simultaneously published in JSCAI.
PE is a serious cardiovascular event where a blood clot causes issues with blood flow and oxygen levels in the lungs. It can be ...
2024-05-03
Long Beach, Calif. – May 3, 2024 – Recent findings from a study on a transcatheter heart valve (THV) system, which includes a new class of transcatheter aortic valve, showed positive results in the device's ability to function as a healthy and natural aortic valve in patients with aortic stenosis (AS). The late-breaking data will be presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
AS is a thickening and narrowing of the aortic valve that can reduce blood flow to ...
2024-05-03
Long Beach, Calif. – May 3, 2024 – Additional analysis from the SMall Annuli Randomized To Evolut or SAPIEN (SMART) study demonstrated clinical non-inferiority of self-expanding valves (SEV) versus balloon-expandable valves (BEV) in aortic stenosis patients undergoing transcatheter aortic valve replacement (TAVR) and confirmed valve performance superiority over time based on hemodynamics. Data also showed similar positive results in two age groups (< or ≥ 80 years old). The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions ...
2024-05-03
Study Title: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
Publication: American Urological Association Annual Meeting Plenary, May 3, 2024
Dana-Farber Cancer Institute author: Xiao X. Wei, MD
Summary: In a follow-on analysis of results from the phase 3 PSMAfore study, clinical investigators from Dana-Farber and elsewhere found that clinical outcomes consistently favored 177Lu-PSMA-617 over a change from one androgen receptor pathway inhibitor (ARPI) to another, regardless of which ARPI patients received first. ...
2024-05-03
Late-Breaking Data Shows Endovascular Therapy Results in One-Third Reduction in Post-Procedural Complications for Women with PAD
Women and Asian Americans Less Likely to Undergo Endovascular Revascularization for PAD Compared to Men and Other Races
Long Beach, Calif. – May 3, 2024 – New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and revascularization. The data ...
2024-05-03
Long Beach, Calif. – May 3, 2024 – New data from the REAL-PE analysis investigated catheter-based pulmonary embolism (PE) treatment, showing women and Black people were less frequently treated with minimally invasive therapy compared to men or non-Black patients. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
...
2024-05-03
WASHINGTON (May 3, 2024) – Children with life-limiting rare diseases and their caregivers face tremendous stress and anxiety about the heart-breaking decisions before them. A new intervention – designed at Children’s National Hospital to support the palliative needs of these families – improved their spiritual and emotional well-being, according to new research published in the journal, Pediatrics.
Called FACE Rare (FAmily CEntered Pediatric Advance Care Planning Intervention for Rare Diseases), the counseling tools were found to be safe, effective and increased feelings of peace among families in this underserved ...
2024-05-03
A research group at the Department of Biochemistry and Molecular Biology of the University of Seville has made a significant advance by discovering the crucial role of the protein Galectin-3 in the progression of various types of brain tumours. In these tumours, the most abundant immune system cells, microglia and macrophages, overexpress Galectin-3, which creates an immunosuppressed environment which inhibits the action of other immune cells against cancer cells.
In vitro findings have shown that specific inhibition of Galectin-3 in microglial cells promotes expression of proinflammatory markers and reverses the presence of key immunosuppressive ...
LAST 30 PRESS RELEASES:
[Press-News.org] ADA Forsyth ranks number 1 on the East Coast in oral health research
The oral health research institute also placed 4th nationally in total NIDCR funding awarded to dental institutions
